← Back to headlines
Novo Nordisk's $475-billion rise and fall as Wegovy-era gains wiped out
Novo Nordisk experienced a significant decline, with its $475-billion gains from the Wegovy era being wiped out.
23 Feb, 16:55 — 23 Feb, 16:55
Sources
Showing 1 of 1 sources
